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OBJECTIVE—Common variants in PPARG, KCNJ11, TCF7L2,
SLC30A8, HHEX, CDKN2A, IGF2BP2, and CDKAL1 genes have
been shown to be associated with type 2 diabetes in European
populations by genome-wide association studies. We have stud-
ied the association of common variants in these eight genes with
type 2 diabetes and related traits in Indians by combining the
data from two independent case–control studies.
RESEARCH DESIGN AND METHODS—We genotyped eight
single nucleotide polymorphisms (PPARG-rs1801282, KCNJ11-
rs5219, TCF7L2-rs7903146, SLC30A8-rs13266634, HHEX-
rs1111875, CDKN2A-rs10811661, IGF2BP2-rs4402960, and
CDKAL1-rs10946398) in 5,164 unrelated Indians of Indo-Euro-
pean ethnicity, including 2,486 type 2 diabetic patients and 2,678
ethnically matched control subjects.
RESULTS—We conﬁrmed the association of all eight loci with
type 2 diabetes with odds ratio (OR) ranging from 1.18 to 1.89
(P  1.6  10
3 to 4.6  10
34). The strongest association with
the highest effect size was observed for TCF7L2 (OR 1.89 [95% CI
1.71–2.09], P  4.6  10
34). We also found signiﬁcant associa-
tion of PPARG and TCF7L2 with homeostasis model assessment
of -cell function (P  6.9  10
8 and 3  10
4, respectively),
which looked consistent with recessive and under-dominant
models, respectively.
CONCLUSIONS—Our study replicates the association of well-
established common variants with type 2 diabetes in Indians and
shows larger effect size for most of them than those reported in
Europeans. Diabetes 59:2068–2074, 2010
T
ype 2 diabetes is a complex metabolic disorder
with both genetic and environmental factors
such as food habits and lifestyle contributing to
its pathogenesis (1). Due to its complex etiology,
the progress of discovery of genetic components for type
2 diabetes had been very slow until the advent of high
throughput genome-wide association (GWA) studies (2).
Until recently, only a few common variants in PPARG (3),
KCNJ11 (4), and TCF7L2 (5) were shown to be associated
with type 2 diabetes. With the advent of GWA studies,
there are at least 20 loci identiﬁed today that are associ-
ated with the risk of type 2 diabetes (6). The ﬁrst GWA
study in the French population revealed SLC30A8 and
HHEX as new loci for type 2 diabetes in addition to
replicating the strong association with TCF7L2 (7). Fur-
ther, GWA studies added several new genes including
CDKAL1, CDKN2A, IGF2BP2, and FTO to the list of type
2 diabetes–associated loci and conﬁrmed the associations
for PPARG, KCNJ11, and TCF7L2 (8–12).
India harbors the maximum number of diabetic patients,
which is projected to double by the year 2030 (13). Indians
are diagnosed with diabetes a decade earlier and at a
lower BMI than Europeans, which may be partly explained
by their excess central obesity (14,15). Hence, determina-
tion of genetic risk factors predicting the risk of type 2
diabetes in the Indian population is highly desirable.
Recent evidence suggests that the genetic basis of several
diseases in Indians might be different from that of Euro-
peans (16,17), which could be due to differences in the risk
allele frequency and pattern of linkage disequilibrium. A
report from the Indian Genome Variation Consortium also
suggested that most of the populations in the Indian
subcontinent are distinct from HapMap populations (18).
Hence, genes associated with a disease in other popula-
tions need to be assessed for their role in the Indian
population. The present study evaluated the association of
eight most replicated and well-established genetic variants
of PPARG, KCNJ11, TCF7L2, SLC30A8, HHEX, CDKN2A,
IGF2BP2, and CDKAL1 with type 2 diabetes and related
quantitative traits in Indians. We also performed allele
dosage analysis of these variants and investigated their
inﬂuence on quantitative metabolic traits related to type 2
diabetes.
RESEARCH DESIGN AND METHODS
The study involved the participation of 5,164 individuals comprising 2,486
patients with type 2 diabetes of Indo-European ethnicity and 2,678 ethnically
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2068 DIABETES, VOL. 59, AUGUST 2010 diabetes.diabetesjournals.orgmatched control subjects recruited from two places—Delhi in northern India
and Pune in western India. Subjects in the Delhi study (comprised of 1,019
patients and 1,006 control subjects) were enrolled on the basis of inclusion
and exclusion criteria as described earlier (19). The consecutive subjects
diagnosed as type 2 diabetic patients according to World Health Organization
criteria (20) at the Endocrinology Clinic of the All India Institute of Medical
Sciences were included in the study. The inclusion criteria for control subjects
were 40 years of age, A1C 6.0%, fasting glucose 6.11 mmol/l, no history
of diabetes in ﬁrst- or second-degree relatives, and urban dweller of Indo-
European ethnicity.
From Pune, 1,467 type 2 diabetic patients and 1,672 control subjects of
Indo-European ethnicity were recruited for the study. Type 2 diabetic patients
were diagnosed before 45 years of age according to World Health Organization
criteria (20). The control group consisted of ethnically matched individuals
recruited from different population cohorts including the Pune Maternal
Nutrition Study, the Pune Children’s Study, and the Coronary Risk of Insulin
Sensitivity in Indian Subjects study (21).
Subjects with ketoacidosis at diagnosis, clinically judged to be insulin
dependent, with exocrine pancreatic disease (ﬁbrocalculous pancreatic dia-
betes), and who fulﬁlled the clinical criteria of maturity-onset diabetes of the
young were excluded from the study. Pregnant women were also excluded
from the study. Informed consent was obtained from all the participants and
the study was approved by the ethics committees of the participating
institutions in accordance with the principles of the Helsinki Declaration.
Clinical measurements. All the subjects in both studies were extensively
characterized for different anthropometric and quantitative metabolic traits.
Anthropometric measurements, including height, weight, and waist and hip
circumferences, were done per standardized protocols, and BMI and waist-
to-hip ratio were calculated. Biochemical measurements including levels of
A1C, fasting plasma glucose (FPG), 2-h postprandial glucose (PPG), fasting
plasma insulin (FPI), total cholesterol, HDL cholesterol, and triglycerides
were performed using standard laboratory assays as described earlier (19,22).
Homeostasis model assessment of insulin resistance (HOMA-IR) was calcu-
lated using the formula: (FPI in mU/ml  FPG in mmol/l)/22.5 and homeosta-
sis model assessment of -cell function (HOMA-B) was calculated using the
equation: (FPI in mU/ml  20)/(FPG in mmol/l  3.5) as reported previously
(23).
Genotyping. Eight well-replicated single nucleotide polymorphisms (SNPs)
from eight genes identiﬁed through GWA studies were selected for association
with type 2 diabetes. These included SNPs-rs1801282 (PPARG), rs5219
(KCNJ11), rs7903146 (TCF7L2), rs13266634 (SLC30A8), rs1111875 (HHEX),
rs10811661 (CDKN2A), rs4402960 (IGF2BP2), and rs10946398 (CDKAL1). In
the samples from Delhi, these eight SNPs were genotyped using Illumina Golden
Gate assay as a part of 1,536-plex assay and following the manufacturer’s
instructions (http://www.illumina.com/downloads/GOLDENGATEASSAY.pdf).
Quality control criteria for the SNPs to qualify for further analysis included:
genotype conﬁdence score of 0.25, call frequency 0.9, GenTrans score
0.6, cluster separation score 0.4, minor allele frequency 0.05, and
Hardy-Weinberg equilibrium (HWE) in control subjects (P  0.0031). A total of
147 samples (7.2%) were genotyped in duplicate, and an error rate of 0.01
was estimated. Further, to validate the genotype calls, 10% of the SNPs were
re-genotyped for 180 samples using Sequenom-based MassARRAY technology,
and a concordance rate of 99.7% was observed.
The genotyping of all the SNPs in the subjects from Pune was performed
using Sequenom-based MassARRAY technology. Genotypes for 10% of the
samples were conﬁrmed by sequencing on an ABI 3730 Genetic Analyzer using
speciﬁc primers, and inconsistency of only 0.06% (2/3,452) was observed.
Statistical analysis. We examined the association of the above-mentioned
SNPs in eight genes with type 2 diabetes and related traits in the Delhi and
Pune studies separately and also after combining the samples from both of the
studies. The distributions of genotype for all the SNPs were analyzed for
deviation from HWE using 
2 analysis. Cochran Q-statistics was performed to
assess heterogeneity between the two groups. Logistic regression analysis
assuming log additive model was performed to determine the association
between SNPs and the risk for type 2 diabetes. The associations were adjusted
for sex, age, BMI, and geographical region, as appropriate. The odds ratios
(ORs) with 95% CIs were presented with respect to the risk allele as observed
in the initial studies on Europeans (9). A P value of  0.0062 (	0.05/8) was
considered signiﬁcant for association with type 2 diabetes in the combined
samples after correcting for multiple testing. The association of each SNP with
continuous traits was performed by pooling the data of control subjects from
both of the studies using the Kruskal-Wallis test. Initially a priori power was
calculated based on the risk allele frequency (RAF) and effect sizes reported
in the Europeans. Subsequently, posterior power calculation was performed
based on the RAF and effect sizes from our study, assuming log additive model
using Quanto software (http://hydra.usc.edu/gxe/) at 	0.05 and 	0.0062
(corrected P value), and assuming 10% prevalence of type 2 diabetes. For
rs7903146 (TCF7L2), we combined the published data of the Pune study (22)
with that of the Delhi study data.
The combined effect of the eight SNPs on the risk of type 2 diabetes was
determined through allele dosage analysis by categorizing the subjects based
on the number of “effective” risk alleles. The analysis included only those
individuals in whom genotypes at all eight SNPs were available. Since the
effect sizes (deﬁned by the SNP-speciﬁc ORs) were not uniform, the allele
dosage score of an individual was computed by the weighted mean of the
proportion of risk alleles at the eight SNPs (i.e., one for two risk alleles, 0.5 for
one risk allele, and 0 for no risk allele) with weights as the relative log ORs of
different SNPs. The “effective” number of risk alleles was obtained as the allele
dosage score multiplied by 16 (maximum number of risk alleles corresponding
to eight SNPs). Considering subjects with six or fewer number of “effective”
TABLE 1
Basic anthropometric and clinical characteristics of the study groups from two centers
Characteristics
Delhi Pune
Type 2 diabetic
patients Control subjects
Type 2 diabetic
patients Control subjects
n (men/women) 1,019 (592/427) 1,006 (606/400) 1,467 (826/641) 1,672 (884/788)
Age (years) 53 (45–62) 50 (44–60) 46 (40–52) 33 (29–37)
Age of diagnosis (years) 45 (39–52) — 38.5 (33.3–42.2) —
Individuals on medication for lipids (%) 4.00 — 22.70 —
BMI (kg/m
2)
Women 26.70 (24.20–29.20) 24.90 (21.10–28.60) 26.90 (24.40–29.60) 19.53 (17.60–22.74)
Men 23.80 (22.00–26.00) 23.20 (20.20–25.70) 24.90 (22.80–27.70) 21.18 (19.15–23.62)
Waist-to-hip ratio
Women 1.00 (0.97–1.03) 0.86 (0.82–0.92) 0.89 (0.85–0.94) 0.76 (0.73–0.80)
Men 1.00 (0.97–1.03) 0.97 (0.92–1.00) 0.97 (0.94–1.02) 0.91 (0.86–0.95)
FPG (mmol/l) 7.90 (6.40–10.30) 4.90 (4.50–5.30) 8.50 (6.90–11.30) 5.11 (4.67–5.56)
2-h PPG (mmol/l) — 5.60 (5.80–6.30) — 5.50 (4.56–6.50)
Total cholesterol (mmol/l) 4.20 (3.50–5.00) 4.40 (3.70–5.10) 4.10 (3.50–4.80) 3.77 (3.28–4.33)
Triglycerides (mmol/l) 1.60 (1.10–2.20) 1.30 (1.00–1.80) 1.40 (1.00–1.20) 0.84 (0.62–1.20)
HDL cholesterol (mmol/l) 1.03 (0.88–1.22) 1.06 (0.88–1.28) 1.03 (0.90–1.18) 1.03 (0.87–1.23)
FPI (pmol/l) — 32.20 (17.50–57.20) — 32.50 (20.84–49.18)
HOMA-IR — 1.16 (0.59–2.02) — 1.21 (0.76–1.89)
HOMA-B — 73.40 (40.70–138.60) — 69.73 (44.39–109.79)
Data are median (interquartile range).
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the number of “effective” risk alleles were calculated after adjusting for sex,
age, BMI, and geographical region. All statistical analyses were performed
using PLINK version 1.05 (http://pngu.mgh.harvard.edu/_purcell/plink) (24)
and SPSS version 17.0 (SPSS, Chicago, IL) unless speciﬁed otherwise.
RESULTS
The clinical characteristics of the subjects in both of the
studies are presented in Table 1. The genotype distribu-
tions at all the SNPs were in HWE (P  0.0031 in control
subjects).
In the Delhi study, the association analysis with type 2
diabetes revealed that all the eight SNPs were signiﬁcantly
associated with type 2 diabetes at 	0.05 and remained
so after adjustment for sex, age, and BMI with ORs ranging
from 1.17 to 1.67 and P values ranging from 0.02 to 1.7 
10
13 (Table 2, and supplementary Table 1 in the online
appendix, available at http://diabetes.diabetesjournals.org/
cgi/content/full/db09-1386/DC1). Consistent with earlier
ﬁndings, we also observed the strongest association at
rs7903146 of TCF7L2 with OR 1.67 (95% CI [1.46–1.92],
P  1.7  10
13).
In the Pune study, all the SNPs except for rs10946398
(CDKAL1) were signiﬁcantly associated with type 2 dia-
betes and retained signiﬁcance after adjusting for sex, age,
and BMI (Table 2, supplementary Table 1). Similar to the
observation in the Delhi study, the TCF7L2 variant
showed the strongest association with OR 2.10 (95% CI
[1.77–2.49], P  1.7  10
17).
There was no signiﬁcant heterogeneity of ORs for any of
the variants between the Delhi and Pune studies (P  0.05
for Cochran Q-statistics), hence we performed association
analysis by combining their genotype data. All the eight
SNPs were signiﬁcantly associated with type 2 diabetes
and adjustment for covariates like age, sex, BMI, and
geographical region did not nullify the signiﬁcance (Table
2, supplementary Table 1). ORs for the associations in the
combined analysis ranged from 1.18 to 1.89 with P values
ranging from 1.6  10
3 to 4.6  10
34. The RAF of three
variants (rs5219, rs7902146, and rs10946398) differed sig-
niﬁcantly between the control subjects of the two studies
(Table 2). Meta-analysis performed by combining the
summary data of the two studies, both under the ﬁxed- and
random-effect models, also conﬁrmed the association of
these SNPs with type 2 diabetes, except for rs5219 under
the random-effect model (supplementary Table 2). The
estimated OR for rs5219 was higher under the random-
effect model than the ﬁxed effect model, which is known
to yield more biased estimates. A priori power calcula-
tions showed that our study had 62% power at 	0.05
and 32% at 	0.0062 (supplementary Table 3) for
detecting the association for the risk of type 2 diabetes
for all SNPs. The effect sizes observed for all variants in
our study populations were higher compared with that
of Europeans (Table 3). However, the CI for two of them
(IGF2BP2 and CDKAL1) included the ORs observed in
Europeans.
Allele dosage analysis revealed a signiﬁcantly enhanced
risk of type 2 diabetes by 1.31-fold with the increase in
TABLE 2
Association of SNPs with type 2 diabetes in the Delhi and Pune studies and the combined study
SNP (gene)
Risk/non-risk
allele*
Delhi
n
Case/
control
subjects
RAF
OR (95% CI)† P
Case
subjects
Control
subjects
rs1801282 (PPARG) C/G 1,019/1,004 0.89 0.86 1.30 (1.08–1.57) 0.006
rs5219 (KCNJ11) T/C 1,017/1,006 0.39 0.35 1.17 (1.02–1.33) 0.02
rs7903146 (TCF7L2) T/C 1,017/1,006 0.40 0.29 1.67 (1.46–1.92) 1.7  10
13
rs13266634 (SLC30A8) C/T 1,010/1,000 0.79 0.75 1.32 (1.13–1.53) 0.0003
rs1111875 (HHEX) G/A 1,018/1,003 0.47 0.42 1.29 (1.13–1.47) 0.0001
rs10811661 (CDKN2A) T/C 1,019/1,006 0.89 0.87 1.3 (1.07–1.59) 0.009
rs4402960 (IGF2BP2) T/G 1,019/1,006 0.46 0.42 1.18 (1.03–1.33) 0.02
rs10946398 (CDKAL1) C/A 1,006/990 0.24 0.21 1.19 (1.03–1.38) 0.02
*Risk alleles as identiﬁed in earlier European studies (9). †Analysis adjusted for sex, age, and BMI. ‡Analysis adjusted for sex, age, BMI, and
geographical region (Delhi and Pune). n, number of subjects genotyped; OR, odds ratio per allele; RAF, risk allele frequency.
TABLE 3
Comparison of effect sizes of the SNPs in Indians and Europeans
Gene SNP
Risk/non-risk
allele*
RAF in
Indians
RAF in
Europeans
Indians† Europeans‡
OR (95% CI) P OR (95% CI) P
PPARG rs1801282 C/G 0.87 0.86 1.37 (1.19–1.59) 1.6  10
5 1.14 (1.08–1.20) 1.7  10
6
KCNJ11 rs5219 T/C 0.31 0.47 1.39 (1.26–1.54) 6.7  10
11 1.14 (1.10–1.19) 6.7  10
11
TCF7L2 rs7903146 T/C 0.24 0.26 1.89 (1.71–2.09) 4.6  10
34 1.37 (1.31–1.43) 1.0  10
48
SLC30A8 rs13266634 C/T 0.77 0.65 1.34 (1.20–1.50) 3.4  10
7 1.12 (1.07–1.16) 5.3  10
8
HHEX rs1111875 G/A 0.43 0.53 1.27 (1.16–1.39) 5.7  10
7 1.13 (1.09–1.17) 5.7  10
10
CDKN2A rs10811661 T/C 0.86 0.83 1.37 (1.18–1.59) 5.1  10
5 1.20 (1.14–1.25) 7.8  10
25
IGF2BP2 rs4402960 T/G 0.44 0.29 1.20 (1.09–1.33) 2.6  10
3 1.14 (1.11–1.18) 8.9  10
36
CDKAL1 rs10946398 C/A 0.24 0.31 1.18 (1.07–1.32) 1.6  10
3 1.12 (1.08–1.16) 4.1  10
11
*Risk alleles in Europeans, as indicated by DGI study (9). †ORs and P values obtained for combined analysis of data from the Delhi and Pune
studies. ‡ORs and P values obtained from combined analysis of the Diabetes Genetics Initiative (DGI), Finland-United States Investigation
of NIDDM Genetics (FUSION), and Wellcome Trust Case Control Consortium (WTCCC) studies (9). OR, odds ratio per allele; RAF, risk allele
frequency.
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39) (Fig.
1). Individuals with 11 or more “effective” risk alleles
(13.64%) carried 6.45-fold increased risk for type 2 diabe-
tes in comparison with individuals having 6 or less “effec-
tive” risk alleles (7.89%) (P  7  10
24).
We then examined the association of genetic variants
with various quantitative traits in the control subjects from
the two studies (Table 4, supplementary Table 5). We
observed signiﬁcant associations for PPARG and TCF7L2
with HOMA-B (P  6.9  10
8 and 3  10
4, respectively).
The association of PPARG looked consistent with a reces-
sive model and that of TCF7L2 looked consistent with an
under-dominant model (heterozygotes have lower
HOMA-B than either of the homozygotes as opposed to
showing a continuous trend across the genotypes). We also
found nominal association of KCNJ11 with FPG (P  0.004),
HOMA-IR (P  0.04), and waist-to-hip ratio (P  0.01);
TCF7L2 with FPG (P  0.03) and 2-h PPG (P  0.03); and
HHEX with FPI (P  0.04) and HOMA-IR (P  0.02).
However, none of the associations for the quantitative trait
analysis, except for PPARG and TCF7L2 with HOMA-B,
remained signiﬁcant after correcting for multiple testing
(Pcorrected  0.000625, 0.05/80).
DISCUSSION
Genome-wide association studies have resulted in the
identiﬁcation of a number of loci associated with type 2
diabetes—from just 3 conﬁrmed loci in 2006 to 20 in 2009
(6). In the present study, we investigated the association of
eight common and well-established common genetic vari-
ants with type 2 diabetes in 5,148 Indians. We combined
the data from two independent studies of Indo-European
individuals to increase the power of the study. To our
knowledge, this is the largest study reported for the
association of type 2 diabetes in Indians.
Among all the loci, TCF7L2 so far has shown the
strongest association with the largest effect size for type 2
diabetes in Europeans (5,7–12), Amish (25), and Indians
(22,26,27), but not in Chinese (28) and Japanese (29)
subjects. The present study conﬁrms the association of
TCF7L2 with type 2 diabetes with the largest effect size.
The TCF7L2 gene product has been implicated in blood
glucose homeostasis (5,30), and the variant rs7903146 is
reported to be associated with measures of glucose me-
tabolism (25). Consistent with these observations, we also
found a strong association of TCF7L2 with HOMA-B and a
nominal association with FPG and 2-h PPG, conﬁrming the
physiological role of TCF7L2 in glucose homeostasis.
Studies evaluating the association of the Pro12Ala vari-
ant of the PPARG gene with type 2 diabetes have reported
contradictory results. The minor allele (Ala) at this locus
has been shown to confer protection against type 2
diabetes by many studies (31–34) while in several other
studies it has been found to predict susceptibility for type
2 diabetes (35,36). Moreover, association analysis of
Pro12Ala in Asian Indians has also shown inconsistent
ﬁndings (27,37) that might be attributed to the differences
in the ethnicity of the subjects in these studies, or the
studies may have been underpowered for detecting the
direction of the association. We established the strong
protective effect of the Ala allele against the development
of type 2 diabetes in Indians.
Variant E23K (rs5219) in KCNJ11 has been shown to be
associated with type 2 diabetes in Europeans and Japa-
nese (4,38) subjects, and our study replicates this signiﬁ-
cant association. The polymorphisms in SLC30A8 and
HHEX were identiﬁed by GWA studies in several Euro-
pean populations and subsequently was replicated in
Asians (38–40). However, the association could not be
validated in the Indian Sikh population, which was prob-
ably due to the small sample size and the low power of the
study (27). With a larger sample size and higher power, we
conﬁrmed the strong association of SLC30A8 and HHEX
SNPs with type 2 diabetes in our combined data. The
variant rs13266634 in SLC30A8 has been shown to be
TABLE 2
Continued
Pune
P
(difference
in allele
frequencies)
Combined
n
Case/
control
subjects
RAF
OR (95% CI)† P
n
Case/
control
subjects
RAF
OR (95% CI)‡ P
Case
subjects
Control
subjects
Case
subjects
Control
subjects
1,422/1,553 0.91 0.87 1.47 (1.15–1.88) 1.8  10
3 0.21 2,441/2,557 0.90 0.87 1.37 (1.19–1.59) 1.6  10
5
1,417/1,397 0.40 0.28 1.84 (1.55–2.18) 4.4  10
12 8.1  10
7 2,434/2,403 0.40 0.31 1.39 (1.26–1.54) 6.7  10
11
1,423/1,515 0.37 0.21 2.10 (1.77–2.49) 1.7  10
17 4.5  10
9 2,439/2,521 0.38 0.24 1.89 (1.71–2.09) 4.6  10
34
1,456/1,539 0.81 0.78 1.25 (1.04–1.51) 0.02 0.03 2,466/2,539 0.80 0.77 1.34 (1.20–1.50) 3.4  10
7
1,454/1,598 0.47 0.43 1.20 (1.03–1.39) 0.02 0.81 2,472/2,601 0.47 0.43 1.27 (1.16–1.39) 5.7  10
7
1,431/1,086 0.89 0.86 1.43 (1.09–1.87) 0.01 0.90 2,450/2,092 0.89 0.86 1.37 (1.18–1.59) 5.1  10
5
1,444/868 0.50 0.46 1.30 (1.08–1.56) 5.5  10
3 0.03 2,463/1,874 0.48 0.44 1.20 (1.09–1.33) 2.6  10
3
1,456/1,512 0.27 0.26 1.17 (0.98–1.38) 0.08 3.3  10
4 2,462/2,501 0.26 0.24 1.18 (1.07–1.32) 1.6  10
3
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any association with either of these parameters.
Variants of the CDKAL1 gene have been linked to
glucotoxicity (8) and have been shown to be associated
with insulin secretion (8), A1C, and HOMA-B (41). We
found signiﬁcant association of the CDKAL1 variant with
type 2 diabetes but with none of the quantitative traits.
We also found signiﬁcant association for the variant
rs10811661, which lies near the CDKN2A gene, with the
risk of type 2 diabetes. This SNP was not associated with
type 2 diabetes in a recent study of Indian Sikhs (27),
stressing on the importance of adequate sample size with
sufﬁcient power. Consistent with previous studies, we also
provided evidence for the association of rs4402960 in
IGF2BP2 with type 2 diabetes (27,38–40).
While all the eight loci independently predicted the risk
for type 2 diabetes, this increased signiﬁcantly if all the
alleles were present together. A 1.31 times enhanced risk
with the increase in each unit of “effective” risk allele and
6.45-fold risk among individuals carrying 11 or more
“effective” risk alleles compared with individuals with 6 or
less “effective” risk alleles underlines the additive inﬂu-
ence of these genetic variants on risk for type 2 diabetes
and their likely role in predictive genetic testing. Further-
more, several variants were found to have higher effect
sizes in our study population in comparison with Europe-
ans. This might be an indication of higher penetration of
these variants for the risk of type 2 diabetes in Indians.
However, the CIs for two of them (IGF2BP2 and CDKAL1)
include the OR estimated in the Europeans suggesting a
similar effect size in both. It is worth mentioning that other
six loci (PPARG, TCF7L2, KCNJ11, SLC30A8, CDKN2A,
and HHEX), whose effect sizes are higher compared with
those of Europeans, also show higher effect sizes when
compared with East Asians (28,29,32–34, 38,39,40). Thus,
the risk alleles at a few type 2 diabetes–associated loci
have higher penetration in Indians compared with Euro-
peans and East Asians subjects.
Population stratiﬁcation is a major confounder for any
association analysis. To address this issue, we have recruited
case and control subjects from the same area for both the
Delhi and Pune studies to minimize the chance for popula-
tion stratiﬁcation in the Indian context (18). However, given
the diversity of Indian population, this possibility cannot be
completely eliminated in the present study.
In conclusion, we replicated the association of eight
major common variants of PPARG, KCNJ11, TCF7L2,
CDKAL1, HHEX, SLC30A8, CDKN2A, and IGF2BP2 with
type 2 diabetes in Indians of Indo-European origin with an
increased effect size compared with Europeans. Although
our study is the largest and is an adequately powered study
that has investigated the genetic basis of type 2 diabetes in
Indians, a larger study of different ethnic groups including
Dravidians will aid in better understanding their penetra-
tion, the likely effect of these genes on various quantitative
traits, and the potential use as diagnostic markers for the
susceptibility to type 2 diabetes in the diabetic capital of
the world.
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